NRG1 and non-small cell lung carcinoma: In 64 evaluable patients with NRG1+ advanced NSCLC, the confirmed ORR was 34% (22/64; [95% CI] 23-47), and the mDOR was 12.9 months, with responses ongoing in 11/22 (50%) patients (66).